AFAdele Fabiano

Adele Fabiano

*This is an algorithmically generated author record based on publicly available information.

Adele Fabiano has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Re-comparing of three different epidemic seasons of bronchiolitis: different prophylaxis approaches

    by Simonetta Picone, Adele Fabiano, Davide Roma, Federico Di Palma, Piermichele Paolillo

    During the last epidemic season of bronchiolitis (S2, years 2016–2017) we performed a single Centre analysis in inborn infant of 30+ 0–32+ 6 gestational age and age < 12 months who did not receive prophylaxis with palivizumab (PLV), in light of the current AIFA (Italian Drug Agency) guidelines restricting the time of the prophylaxis to those born < 30 weeks of gestational age. During that epidemic season, we observed a rising trend of bronchiolitis-related hospitalization and an increased rate of mechanical ventilation in preterm child compared to the previous one (S1, years 2015–2016) during which infants of this same gestational age received palivizumab (PLV) prophylaxis, according to the 2015 Italian Guidelines. In light of the revised AIFA guidelines (November 2017), allowing once again prophylaxis with PLV in infants of > 30 weeks gestational age, we decided to repeat our observation during the last epidemic season (S3, years 2017–2018), in order to compare ours infants of 30+ 0–32+ 6 gestational age with preterm of the same gestational age born in our unit in the previous seasons (S1 and S2), to evaluate the clinical impact of the different prophylaxis approaches. The new observation confirmed the clinical efficacy of PLV in this delicate group of newborns in preventing almost completely new episodes of bronchiolitis. Of the 6 newborns who developed bronchiolitis, 4 had received only a single dose of PLV, providing suboptimal protection, before the onset of bronchiolitis; furthermore 3 developed a mild form allowing to be treated at home.


  • Open Access

    Comparing of two different epidemic seasons of bronchiolitis

    by Simonetta Picone, Adele Fabiano, Davide Roma, Piermichele Paolillo

    Acute bronchiolitis is the most common cause of hospitalizations in infants < 12 months of age and preventive efforts remain the most important strategy to date. Recently prophylaxis with palivizumab (PLV) was limited to preterm infants with < 29 weeks gestational age (wGA). We performed a single center analysis in preterm infants (GA between 30 and 32 weeks) and age < 12 months to compare prophylaxis with PLV and frequency and characteristics of bronchiolitis and bronchiolitis-related hospitalization in two consecutive epidemic seasons (S1 vs S2). We found a rising trend in rate of bronchiolitis and bronchiolitis-related hospitalization in S1 vs S2. Among hospitalization, we found an increased morbidity with an increase in the rate of mechanical ventilation in S2. Additionally, hospitalization occurred in subjects with younger chronological age in S2 compared with S1. Our result cannot be generalized because deriving from a single Center and further evaluation on wider simple size are warranted, but it suggests an increase in the incidence, gravity and precocity of bronchiolitis in 29–32 wGE preterm infants with the change in National guidelines for prophylaxis.